See more : S&S Tech Corporation (101490.KQ) Income Statement Analysis – Financial Results
Complete financial analysis of Sigilon Therapeutics, Inc. (SGTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Sigilon Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- NGL Energy Partners LP (NGL) Income Statement Analysis – Financial Results
- Bertrandt Aktiengesellschaft (BDT.DE) Income Statement Analysis – Financial Results
- SMC Global Securities Limited (SMCGLOBAL.BO) Income Statement Analysis – Financial Results
- Context Therapeutics Inc. (CNTX) Income Statement Analysis – Financial Results
- Kenadyr Metals Corp. (KNDYF) Income Statement Analysis – Financial Results
Sigilon Therapeutics, Inc. (SGTX)
About Sigilon Therapeutics, Inc.
Sigilon Therapeutics, Inc., a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of mucopolysaccharidosis type 1; SIG-007 to provide continuous and prolonged release of functional enzyme at levels sufficient to produce clinical benefits and alleviate progression of the downstream aspects of Fabry disease; and SIG-002 to replace islet cells for the treatment of type 1 diabetes. Sigilon Therapeutics, Inc. has a research collaboration and license agreement with Eli Lilly and Company for the development and commercialization of SLTx product candidates for the treatment of Type 1 Diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Revenue | 12.94M | 9.60M | 13.37M | 14.16M | 4.64M |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 12.94M | 9.60M | 13.37M | 14.16M | 4.64M |
| Gross Profit Ratio | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 37.63M | 65.07M | 53.49M | 48.11M | 21.04M |
| General & Administrative | 18.98M | 20.17M | 12.53M | 10.17M | 6.67M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 18.98M | 20.17M | 12.53M | 10.17M | 6.67M |
| Other Expenses | 1.45M | 55.00K | -89.00K | -6.00K | -81.00K |
| Operating Expenses | 56.61M | 85.24M | 66.02M | 58.28M | 27.71M |
| Cost & Expenses | 56.61M | 85.24M | 66.02M | 58.28M | 27.71M |
| Interest Income | 946.00K | 258.00K | 312.00K | 1.06M | 698.00K |
| Interest Expense | 2.29M | 1.99M | 1.20M | 650.00K | 289.00K |
| Depreciation & Amortization | 2.40M | 313.00K | 223.00K | 1.73M | 374.00K |
| EBITDA | -41.27M | -75.32M | -52.42M | -42.40M | -22.08M |
| EBITDA Ratio | -318.84% | -784.70% | -391.95% | -299.51% | -476.26% |
| Operating Income | -43.67M | -75.64M | -52.64M | -44.12M | -23.08M |
| Operating Income Ratio | -337.35% | -787.96% | -393.61% | -311.71% | -497.63% |
| Total Other Income/Expenses | 105.00K | -1.68M | -1.97M | 198.00K | 310.00K |
| Income Before Tax | -43.56M | -77.31M | -54.61M | -43.93M | -22.77M |
| Income Before Tax Ratio | -336.53% | -805.41% | -408.31% | -310.31% | -490.94% |
| Income Tax Expense | -105.00K | 925.00K | 259.00K | 644.00K | 599.00K |
| Net Income | -43.46M | -78.24M | -54.87M | -44.57M | -22.77M |
| Net Income Ratio | -335.72% | -815.04% | -410.25% | -314.86% | -490.94% |
| EPS | -1.34 | -31.92 | -22.67 | -27.53 | -18.85 |
| EPS Diluted | -1.34 | -31.92 | -22.67 | -27.53 | -18.85 |
| Weighted Avg Shares Out | 32.41M | 2.45M | 2.42M | 1.62M | 1.21M |
| Weighted Avg Shares Out (Dil) | 32.41M | 2.45M | 2.42M | 1.62M | 1.21M |
Sigilon Therapeutics, Inc. (SGTX) Reports Q2 Loss, Tops Revenue Estimates
Sigilon Therapeutics, Inc. (SGTX) Reports Q1 Loss, Tops Revenue Estimates
Sigilon Therapeutics to Present at the Needham Healthcare Conference
Sigilon Therapeutics, Inc. (SGTX) Reports Q4 Loss, Misses Revenue Estimates
Sigilon Therapeutics to Present at the Barclays Global Healthcare Conference
4 Small Drug Stocks That Appear to Be Solid Bets in a Challenging Industry
Bears are Losing Control Over Sigilon Therapeutics, Inc. (SGTX), Here's Why It's a 'Buy' Now
BMEZ: Buy Low, Hold For The Distribution And Rebound
Sigilon Therapeutics to Present Preclinical Data at the 18th Annual WORLDSymposium™ on Lysosomal Diseases, MPS-1 and MPS-6
Sigilon Therapeutics Issues An Update On Its Early-Stage Hemophilia Study
Source: https://incomestatements.info
Category: Stock Reports